Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02138812
Title Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer

Advanced Solid Tumor

triple-receptor negative breast cancer


BAY1161909 + Paclitaxel

Age Groups: adult
Covered Countries USA

No variant requirements are available.